欢迎您访问中乔新舟官网!400-038-9959我的购物车(0)
您当前的位置:首页 > 产品中心
SU-DHL-10急性淋巴细胞 (STR鉴定)
英文名:SU-DHL-10
货号:ZQ0581
价格:¥1500.00
加入购物车,提交订单信息之后,我们会第一时间与您取得联系!
推荐组合

SU-DHL-10急性淋巴细胞 (STR鉴定)

¥1500.00
+

SU-DHL-10急性淋巴细胞专用培养基

¥350.00 ¥450.00

配套完培,省时省力,单买细胞无优惠

=

细胞套餐惊爆价

¥1850 ¥2250.00
加入购物车
  • 产品说明
  • 产品规格
  • 参考文献
  • STR鉴定

产品名称

SU-DHL-10急性淋巴细胞

货号

ZQ0581

产品介绍

SU-DHL-10是一种人B细胞淋巴细胞系,是1978年从患有大细胞淋巴瘤的25岁白人男性的淋巴结中分离的,该男性患有大细胞淋巴瘤(弥漫性组织细胞淋巴瘤),细胞系携带EZH2 Y641F突变。细胞形态为淋巴母细胞样,生长特性为悬浮生长,多细胞聚集。
SU-DHL-10细胞系具有多种应用,具体包括但不限于以下几个方面:淋巴瘤分子病理分型研究、药物筛选和敏感性测试、细胞信号传导研究、白血病干细胞研究、基因和蛋白质功能研究、免疫逃逸机制研究、基因突变和异质性研究等。SU-DHL-10细胞系的这些应用展示了其在血液癌症研究中的多方面价值,为理解淋巴瘤的复杂性、开发新的治疗方法以及提高患者的生存率做出了重要贡献。
 

种属

性别/年龄

男/25岁

组织

淋巴结

疾病

大细胞淋巴瘤

细胞类型

肿瘤细胞

形态学

淋巴母细胞样

生长方式

悬浮;多细胞聚集体

倍增时间

大约15~30小时

培养基和添加剂

RPMI-1640基础培养基(中乔新舟 货号:ZQ-200+10%胎牛血清(中乔新舟 货号:ZQ0500)+1%P/S(中乔新舟  货号:CSP006

推荐完全培养基货号

ZM0581

生物安全等级

BSL-1

STR位点信息

D5S818: 11, 12 
D13S317: 10, 11 
D7S820: 8, 11 
D16S539: 10, 11 
vWA: 17 
THO1: 8, 9.3 
TPOX: 8 
CSF1PO: 10, 13 
Amelogenin: XY

培养条件

95%空气,5%二氧化碳;37℃

抗原表达/受体表达

*** 

基因表达

*** 

保藏机构

ATCC; CRL-2963 DSMZ; ACC-576

供应限制

仅供科研使用

货号

ZQ0581

发货规格

活细胞:T25培养瓶*1瓶或者1ml 冻存管*1支(细胞量约为5 x 10^5 cells/vial)二选一

发货形式

活细胞:常温运输;冻存管:干冰运输

储存温度

活细胞:培养箱;冻存管:液氮罐

产地

中国

供应限制

仅供科研使用


1、PubMed=23257783; DOI=10.1038/leu.2012.367
Wenzel S.-S., Grau M., Mavis C., Hailfinger S., Wolf A., Madle H., Deeb G., Dorken B., Thome M., Lenz P., Dirnhofer S., Hernandez-Ilizaliturri F.J., Tzankov A., Lenz G.
MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma.
Leukemia 27:1381-1390(2013)


2、PubMed=25355872; DOI=10.1128/JVI.02570-14
Cao S.-B., Strong M.J., Wang X., Moss W.N., Concha M., Lin Z., O'Grady T., Baddoo M., Fewell C., Renne R., Flemington E.K.
High-throughput RNA sequencing-based virome analysis of 50 lymphoma cell lines from the Cancer Cell Line Encyclopedia project.
J. Virol. 89:713-729(2015)


3、PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)


4、PubMed=25877200; DOI=10.1038/nature14397
Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.
A resource for cell line authentication, annotation and quality control.
Nature 520:307-311(2015)


5、PubMed=26589293; DOI=10.1186/s13073-015-0240-5
Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Genome Med. 7:118.1-118.7(2015)


6、PubMed=26727417; DOI=10.3109/10428194.2015.1108414
Drexler H.G., Eberth S., Nagel S., MacLeod R.A.F.
Malignant hematopoietic cell lines: in vitro models for double-hit B-cell lymphomas.
Leuk. Lymphoma 57:1015-1020(2016)


7、PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)


8、PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)


9、PubMed=29416618; DOI=10.18632/oncotarget.20378
Liu W., Chen J., Tamayo A.T., Ruan C.-G., Li L., Zhou S.-H., Shen C., Young K.H., Westin J., Davis R.E., Hu S.-M., Medeiros L.J., Ford R.J. Jr., Pham L.V.
Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma.
Oncotarget 9:346-360(2018)


10、PubMed=29666304; DOI=10.1158/1078-0432.CCR-17-3004
Pham L.V., Huang S.-J., Zhang H., Zhang J., Bell T., Zhou S.-H., Pogue E., Ding Z.-Y., Lam L., Westin J., Davis R.E., Young K.H., Medeiros L.J., Ford R.J. Jr., Nomie K., Zhang L., Wang M.
Strategic therapeutic targeting to overcome venetoclax resistance in aggressive B-cell lymphomas.
Clin. Cancer Res. 24:3967-3980(2018)


11、PubMed=30285677; DOI=10.1186/s12885-018-4840-5
Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X., Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H., Koeffler H.P.
Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines.
BMC Cancer 18:940.1-940.13(2018)


12、PubMed=30629668; DOI=10.1371/journal.pone.0210404
Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.
Screening human cell lines for viral infections applying RNA-Seq data analysis.
PLoS ONE 14:E0210404-E0210404(2019)


13、PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)


14、PubMed=30971826; DOI=10.1038/s41586-019-1103-9
Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M., Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R., Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P., van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L., Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Nature 568:511-516(2019)


15、PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)


16、PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

公司简介 / Company profile
上海中乔新舟生物科技有限公司
Shanghai Zhong Qiao Xin Zhou Biotechnology Co.,Ltd.
           上海中乔新舟生物科技有限公司(官网:www.zqxzbio.com)成立于2011年,历经...
联系我们 / Contact
电 话:021-56760357;021-56760351
传 真:
邮 箱:sales@zqxzbio.com
邮 编:200439
地 址:上海市宝山区长江南路180号
Copyright © 2014 ZQXZBIO All rights reserved.
技术支持:中乔新舟沪ICP备14008091号